Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493451 | 0.97 | KMT2A (0.45) | KMT2ATP53ALDH1A1MEN1CYP3A4 | |
| SCHEMBL492911 | 0.93 | KMT2A (0.42) | KMT2AALDH1A1MEN1SMN1; SMN2TSHR | |
| SCHEMBL492470 | 0.93 | KMT2A (0.42) | KMT2AALDH1A1MEN1SMN1; SMN2TSHR | |
| SCHEMBL492609 | 0.93 | ALDH1A1 (0.48) | KMT2AALDH1A1MEN1SMN1; SMN2TSHR | |
| SCHEMBL493390 | 0.93 | ALDH1A1 (0.46) | KMT2AALDH1A1MEN1SMN1; SMN2TSHR | |
| SCHEMBL492878 | 0.92 | KMT2A (0.42) | KMT2ATP53ALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL492719 | 0.92 | MEN1 (0.41) | KMT2AALDH1A1MEN1SMN1; SMN2CYP3A4 | |
| SCHEMBL494257 | 0.92 | KMT2A (0.42) | KMT2AALDH1A1MEN1SMN1; SMN2CYP3A4 | |
| SCHEMBL493423 | 0.91 | CCL5 (0.38) | KMT2ATP53ALDH1A1MEN1CYP3A4 | |
| SCHEMBL493775 | 0.89 | EPHX2 (0.42) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | KMT2A 1749/4885TP53 4136/4885ALDH1A1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.